PT  - JOURNAL ARTICLE
AU  - Lin, Jiaji
AU  - Lu, Haoxuan
AU  - Zhang, Dekang
AU  - Bian, Xianbing
AU  - Hu, Jianxing
AU  - Pan, Longsheng
AU  - Lou, Xin
TI  - Fibrinogen and hypertension are key factors associated with tremor relieve and recurrence in the ET patients subjected with MRgFUS thalamotomy
AID  - 10.1101/2024.02.14.24302845
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.14.24302845
4099  - http://medrxiv.org/content/early/2024/02/15/2024.02.14.24302845.short
4100  - http://medrxiv.org/content/early/2024/02/15/2024.02.14.24302845.full
AB  - Background There were variable differences and declines in efficacy of magnetic resonance guided focused ultrasound (MRgFUS) thalamotomy, but whether the clinical status of these patients was involved was still unknown.Methods We retrospectively reviewed the tremor symptoms and clinical variables (at hospitalization) of 59 essential tremor (ET) patients subjected with MRgFUS thalamotomy. Patients were categorized by the short-term tremor relieve, tremor recurrence within 12 months and long-term maintenance outcome. Multivariate logistic regression was used to screen independent factors and construct the nomogram. Additional harmaline-induced ET model in male ICR mice were employed, we evaluated the possible anti-tremor effects of fibrinogen knock-out.Results MRgFUS thalamotomy resulted in significant tremor relieve, multivariate analysis suggested fibrinogen (OR = 0.182, 95% CI = 0.042-0.796,) and monocyte count (OR = 0, 95% CI = 0-0.001) were independently associated with better short-term tremor relieve (>75%) at 1-month postoperatively. A total of nine ET patients (15.254%) experienced significant tremor recurrence. Admission systolic blood pressure (OR = 1.013, 95% CI = 1.010-1.062), hypertension comorbidity (OR = 2.163, 95% CI = 1.412-53.565) and fibrinogen (OR = 1.620, 95% CI = 1.047-24.376) independently contributed to tremor recurrence. There were 15 ET patients (25.424%) sustained long-term and effective tremor control. Only admission systolic blood pressure was the independent prognostic factor (OR = 0.880, 95% CI = 0.785-0.987) for this favorable outcome. The nomograms were established for better tremor relieve and tremor recurrence and have excellent performance as the AUCs were 0.829 and 0.853 (bootstrap repetition = 1000). Finally, FGB knock-out significantly suppressed harmaline-induced tremor in vivo (P < 0.001).Conclusion Fibrinogen and hypertension are key factors associated with tremor relieve and recurrence in the ET patients subjected with MRgFUS thalamotomy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by National Natural Science Foundation of China 82151309, 81825012 and 81730048 to XL as well as China Postdoctoral Science Foundation 2022T150788 to JJL.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Demographic and clinical information for this observational, retrospective, single-center study was collected from Chinese PLA General Hospital. It was approved by the institutional review board and the independent scientific advisory committee at Chinese PLA General Hospital. The data were anonymous, and the requirement for informed consent was therefore waived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes